Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect study of relacorilant in healthy subjects
NCT06094738Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of relacorilant in Cushing's syndrome (3 arms), sponsored by Corcept Therapeutics. Primary endpoints: Area under the concentration-time curve from time zero to the last observed concentration at Day 5, Area under the concentration-time curve from time zero extrapolated to infinity at Day 5 and 1 more. Started Sep 2020; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT06094738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094738.